A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

NCT01094288 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Adenocarcinoma of the Prostate

Interventions

DRUG: Alisertib
DRUG: Docetaxel

Sponsor

Millennium Pharmaceuticals, Inc.